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ABSTRACT: Trialkylphosphines tris(2-carboxy-ethyl)-phosphine and tris(3-hydroxyprop-
yl)-phosphine are popular reagents for the reduction of cysteine residues in bioconjugation
reactions using maleimides. However, it has been demonstrated that these phosphines are
reactive toward maleimide, necessitating their removal before the addition of the Michael
acceptor. Here, a method using water-soluble PEG-azides is reported for the quenching of
trialkylphosphines in situ, which is demonstrated to improve the level of maleimide
conjugation to proteins.
■ INTRODUCTION
The water-soluble trialkylphosphines, tris(2-carboxy-ethyl)-
phosphine 1 (TCEP) and tris(3-hydroxypropyl)-phosphine 2
(THPP), are eﬀective reagents for the reduction of disulﬁdes
before performing protein-conjugation reactions using Michael
acceptors such as maleimides (Figure 1a).1−5 Reactions such as
these are important within the pharmaceutical industry for the
manufacture of several types of products including antibody−
drug conjugates, PEGylated proteins, and conjugate vaccines.
Preference for the use of TCEP and THPP over traditional
thiol-based reducing agents can be attributed to a number of
practical advantages. TCEP and THPP are relatively stable
toward aerial oxidation at pH values common for protein
conjugations, as well as being nonvolatile and relatively
odorless.6,7 Importantly, reduction of cysteinyl residues by
these phosphines does not result in the formation of mixed
disulﬁdes, as is the case with traditional thiols such as
dithiothreitol and 2-mercaptoethanol.7−10
Early reports on the use of TCEP in protein conjugation
strategies suggested that this phosphine was compatible with
maleimide and did not need to be removed before the addition
of the Michael acceptor.2,11−13 A number of recent reports,
however, have conﬁrmed that TCEP and THPP do indeed
react with maleimides to reduce conjugation yields signiﬁ-
cantly.8,14−17 Importantly, it has also been demonstrated that
ylenes formed between maleimide and TCEP, such as 3, are
remarkably stable under physiological conditions and can
remain incorporated in the products of some protein
conjugations (Figure 1b).16 As such, it is advantageous to
remove the phosphine from the reaction before the addition of
maleimide.
A variety of methods are available for the removal of TCEP
(e.g., dialysis, TCEP-immobilized resin, column chromatog-
raphy); however, each has associated drawbacks.14 As an
alternative, Henkel et al. have reported an elegant approach that
uses 4-azidobenzoic acid (4-ABA) 4 to quench excess TCEP
through a Staudinger reaction, thus circumventing the need for
a puriﬁcation step when using phosphines in maleimide-based
bioconjugations (Figure 1c).17
In our hands, however, we have found the application of this
method to be limited by the low aqueous solubility of 4, which
necessitated increased reaction volumes, thereby reducing the
substrate concentrations and reaction rates. Here, we describe
the use of azide-modiﬁed polyethylene glycols as water-soluble
reagents for the quenching of TCEP and THPP in situ to
improve yields of protein conjugation reactions using
maleimide.
■ RESULTS AND DISCUSSION
A series of azide-containing ethylene glycols of increasing
molecular weights were initially chosen to determine the eﬀect
of polymer length on their aqueous solubility and on reactivity
toward TCEP. Diazido-ethylene glycols 5−8 are all available
commercially or, alternatively, can each be synthesized in good
yields following established methods (Scheme 1).
The mass and molar solubilities of PEG-azides 5−8 were
determined in a 0.1 M Tris−HCl buﬀer at pH 7, and all azides
were found to be readily soluble in this buﬀer system with
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values ranging from 25 mg/mL for the di-PEG 5, up to 130
mg/mL for the penta-PEG 8 (Table 1). By comparison, 4-ABA
(4) was found to have a signiﬁcantly lower mass solubility
under similar conditions (Table 1). The solubility of 4 could be
increased using diﬀerent solvent systems, such as 50% aqueous
methanol or Tris−HCl buﬀer at pH 8.0. However, solvent
systems such as these are suboptimal for performing maleimide
conjugation reactions with proteins.
The ability of azides 5−8 to quench TCEP and THPP by
promoting oxidation was then evaluated using 31P NMR
spectroscopy to quantify the rate of consumption of phosphine.
Solutions of TCEP (25 mM) and PEG-azide (10 equiv) were
monitored every 10 min (31P NMR), with all azides promoting
rapid oxidation of TCEP. Azides 5−7 were found to have
similar reactivities, with complete consumption of TCEP
occurring after 50−60 min (Figure 2). The penta-PEG azide,
8, was found to react slightly more rapidly, with complete
Figure 1. (a) General method for the synthesis of protein conjugates by reduction and conjugate addition to thiols. (b) Reactions of TCEP (1) and
THPP (2) with N-ethylmaleimide to give the ylene 3 and N-ethylsuccinimide, respectively.16 (c) Oxidation of TCEP using 4-azidobenzioc acid 4
reported by Henkel et al.17
Scheme 1. Chemical Synthesis of PEG-Azides 5−8
Table 1. Summary of the Mass and Molar Aqueous
Solubilities Measured for PEG-Azides 5−8 and 4-ABA 4
solubility
compound solvent mg/mL mM
4 0.1 M Tris−HCl buﬀer (pH 7.0) 0.5 3
4 0.1 M Tris−HCl buﬀer (pH 8.0) 4.4 27
4 50% MeOH/water 1.5 9
5 0.1 M Tris−HCl buﬀer (pH 7.0) 25 125
6 0.1 M Tris−HCl buﬀer (pH 7.0) 60 246
7 0.1 M Tris−HCl buﬀer (pH 7.0) 88 304
8 0.1 M Tris−HCl buﬀer (pH 7.0) 130 356
Figure 2. Oxidation rates of TCEP in the presence of PEG-azides 5−8
(250 mM) in a 0.1 M Tris−HCl buﬀer. Remaining TCEP (%) was
determined using 31P NMR spectroscopy.
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oxidation of the phosphine occurring after only 40 min.
Similarly, all of the azides (5−8) were found to promote the
oxidation of THPP under similar conditions to those used for
the oxidation of TCEP; however, oxidation occurred at much
higher rates and complete consumption of THPP was observed
in less than 5 min.
Having established that all of the PEG-azides, 5−8, can
eﬀectively promote rapid oxidation of TCEP and THPP under
conditions suitable for performing maleimide-based protein
conjugation reactions, it was necessary to consider potential
side reactions that might occur from their use in situ in a
conjugation mixture. In particular, the ability of alkyl azides to
react with maleimide to form triazoles is reported in the
literature, typically using organic solvents at elevated temper-
atures.18 To investigate the potential for PEG-azides to form
triazoles with maleimide in an aqueous buﬀer at an ambient
temperature, the tetra-PEG azide, 7, was treated with N-
ethylmaleimide (9) for 2.5 days, which resulted in the
formation of both the monotriazole (10) and ditriazole (11)
derivatives isolated in 42 and 25% yields, respectively (Scheme
2). Despite this observation, it was considered that the cross-
reaction with maleimide was unlikely to interfere with the use
of PEG-azides in situ during protein conjugation strategies
given the very slow rate of triazole formation (days) compared
to typical rates of maleimide reaction with thiols (min−h).
The use of PEG-azides to improve the yield of
bioconjugation reactions was then evaluated in applications in
which maleimide is commonly employed as a Michael acceptor.
The functionalization of proteins using maleimide-derivatized
ﬂuorescent labels is often used to enable visualization of
proteins, with a number of these reagents, for example, N-(5-
ﬂuorescinyl)maleimide (12), being commercially available
(Figure 3a).15,19,20 Tyagarajan et al. have demonstrated
previously that the level of labeling of yeast enolase protein
(which contains a single internal cysteine and requires
denaturation for conjugation to occur) by maleimide-
containing ﬂuorescent dyes is signiﬁcantly diminished when
performing the conjugation reaction in the presence of
TCEP.15 We sought to evaluate the impact that the use of
PEG-azides in situ would have on the level of ﬂuorescent
labeling of yeast enolase using 12. Denatured yeast enolase was
treated with varying amounts of TCEP (1, 5, or 10 equiv) and
then incubated with 12. In a parallel experiment, TCEP-treated
enolase samples were incubated with PEG-azide 7 for 1 h
before the addition of compound 12. The ﬂuorescently labeled
enolase protein was then resolved using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), and the level
of maleimide conjugation was evaluated by visualization at 525
nm (Dark Reader). Here, the degree of ﬂuorescent labeling of
yeast enolase was observed to decrease with increasing amounts
of TCEP (Figure 3b, lanes 1−3), consistent with the previous
observations of Tyagarajan et al. Signiﬁcantly, in the presence
of both 5 and 10 equiv of TCEP (Figure 3b, lanes 2 and 3,
respectively), labeling by maleimide was essentially abolished.
However, for enolase samples treated with PEG-azide 7 before
the addition of 12, there appeared to be little diﬀerence
Scheme 2. Reaction of PEG-Azide 7 with N-Ethylmaleimide 9 (1.5 equiv) To Give Monotriazole 10 and Ditriazole 11, in 42 and
25% Yields, Respectively
Figure 3. Fluorescent labeling of yeast enolase in the presence or absence of PEG-azide 7. (a) Chemical structure of the ﬂuorescein-maleimide label
12. (b) Lanes 1−3: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA) was incubated with TCEP (1, 5, or 10 mM) for 45
min (RT) and then treated with 12 (1 mM) for 18 h (37 °C). Lanes 4−6: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA)
was treated with TCEP (1, 5, or 10 mM) for 45 min (RT) and then incubated with 7 (100 mM) for 1 h (37 °C) before the addition of 12 (1 mM)
for 18 h (37 °C). (c) Lanes 1−3: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA) was incubated with THPP (1, 5, or 10
mM) for 45 min (RT) and then treated with 12 (1 mM) for 18 h (37 °C). Lanes 4−6: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5
mM EDTA) was treated with THPP (1, 5, or 10 mM) for 45 min (RT) and then incubated with 7 (100 mM) for 1 h (37 °C) before the addition of
12 (1 mM) for 18 h (37 °C). All protein samples were resolved by SDS-Page (4−12% gradient gel) and ﬂuorescence visualized at 525 nm (Dark
Reader).
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between the amount of TCEP used and the extent of
ﬂuorescent labeling, with all samples showing signiﬁcant levels
of ﬂuorescence (Figure 3b, lanes 4−6). Similarly, when the
above experiment was repeated using THPP as the reducing
agent, ﬂuorescent labeling was again seen to decrease
signiﬁcantly with increasing amounts of the phosphine in the
absence of azide 7 (Figure 3c, lanes 1−3). In the presence of
azide 7, however, the amount of THPP used did not appear to
inﬂuence the extent of conjugation (Figure 3c, lanes 4−6),
consistent with the results observed for TCEP-treated enolase.
As such, the preincubation of TCEP- or THPP-treated enolase
with PEG-azide 7 before maleimide addition was found to
improve the level of ﬂuorescent conjugation regardless of the
amount of the phosphine used.
Another important application of maleimide for conjugation
to proteins involves the attachment of large PEG polymers
(kDa’s), a technique used widely within the pharmaceutical
industry to improve the pharmacokinetic properties of protein
therapeutics. Here, it was considered that investigating the use
of azides 5−8 in situ in protein PEGylation reactions would
also facilitate the quantiﬁcation of any improvements to
conjugation, as PEGylated protein products could be resolved
on the basis of their mass (SDS-PAGE). In addition, the use of
excess PEG-maleimide to protein (100 equiv) would identify
whether any nonspeciﬁc conjugation was occurring, as multiple
higher-molecular-weight products would be observed. Dena-
tured yeast enolase protein was reduced with varying amounts
of TCEP (1, 5, and 10 equiv) and then incubated with 2 kDa
PEG-maleimide. In parallel, samples of the TCEP-reduced
enolase were treated with azide 7 for 1 h, before incubation
with 2 kDa PEG-maleimide under similar conditions. All
samples were then resolved (SDS-PAGE), and the presence of
protein was detected by staining with Coomassie Brilliant Blue.
To determine the level of protein PEGylation, SDS gels were
scanned (LI-COR Odyssey CLx) to quantify the intensity of
Coomassie-stained protein bands. Figure 4a shows that the
extent of protein PEGylation decreases signiﬁcantly from 42 to
11% with increasing amounts of TCEP when treated with 2
kDa PEG-maleimide directly following reduction (lanes 3−5).
In contrast, for enolase incubated with azide 7 before
incubation with 2 kDa PEG-maleimide, increased levels of
PEGylation were observed for all samples (76−85%),
regardless of the TCEP concentration used (Figure 4a, lanes
6−8). Worthy of mention is that, in the presence of equal
molar amounts of maleimide to TCEP, only 42% conjugation is
observed following direct treatment with PEG-maleimide (lane
3), whereas the level of conjugation rises to 76% following
removal of TCEP by 7 before the addition of maleimide (lane
6). This suggests that the relative rates of reaction between
maleimide with either cysteine or TCEP are comparable,
consistent with previous observations by Kantner.16 Similar
results were also observed using THPP as the reducing agent.
Figure 4. Functionalization of yeast enolase with 2 kDa PEG-maleimide in the presence or absence of 7. (a) Lane 1: protein marker; lane 2: yeast
enolase control; lanes 3−5: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA) was incubated with TCEP (1, 5, or 10 mM)
for 45 min (RT) and then treated with 2 kDa PEG-maleimide (1 mM) for 18 h (37 °C). Lanes 6−8: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5
M, pH 7.2, 5 mM EDTA) was treated with TCEP (1, 5, or 10 mM) for 45 min (RT) and then incubated with 7 (100 mM) for 1 h (37 °C) before
the addition of 2 kDa PEG-maleimide (1 mM) for 18 h (37 °C). (b) Lane 1: protein marker; lane 2: yeast enolase control; lanes 3−5: Yeast enolase
(11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA) was incubated with THPP (1, 5, or 10 mM) for 45 min (RT) and then treated with 2
kDa PEG-maleimide (1 mM) for 18 h (37 °C). Lanes 6−8: Yeast enolase (11 μM) in Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM EDTA) was treated
with THPP (1, 5, or 10 mM) for 45 min (RT) and then incubated with 7 (100 mM) for 1 h (37 °C) before the addition of 2 kDa PEG-maleimide (1
mM) for 18 h (37 °C). All protein samples were resolved by SDS-Page (4−12% gradient gel) and stained using Coomassie blue solution. PEGylated
enolase (%) was determined by scanning each band (n = 3) using a LI-COR Odyssey CLx and calculating the ratio of PEGylated enolase/total
enolase (Image Studio Lite).
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Treatment of denatured enolase with 2 kDa PEG-maleimide
immediately following reduction showed signiﬁcant levels of
unmodiﬁed protein (Figure 4b, lanes 3−5), whereas incubation
of the reduced protein with 7 before the addition of maleimide
resulted in high levels of PEGylation for all concentrations of
THPP used (Figure 4b, lanes 6−8). Interestingly, the highest
overall levels of protein PEGylation were observed using a 10:1
ratio of the phosphine (TCEP or THPP) when incubated with
7 before the addition of maleimide (Figure 4a, lane 8; and
Figure 4b, lane 8). Conversely, the poorest levels of conjugation
were seen when using this same 10:1 ratio of the phosphine in
the absence of 7 (Figure 4a, lane 3; and Figure 4b, lane 3). This
observation could result from more extensive reduction (more
thiol present) as a consequence of the ability to use higher
TCEP concentrations, given that all excess TCEP is now being
removed through the use of PEG-azides.
■ CONCLUSIONS
In summary, we have shown here that PEG-azides 5−8 have
suitable aqueous solubilities to enable their use in bioconjuga-
tion strategies employing maleimide and that all of these azides
aﬀect the rapid oxidation of both TCEP and THPP.
Furthermore, it has been observed that the treatment of
phosphine-reduced protein with PEG-azides such as 7 in situ,
before the addition of the maleimide, allows for the use of high
TCEP concentrations and leads to improved levels of
conjugation using both small ﬂuorescent probes and higher-
molecular-weight PEGs.
■ EXPERIMENTAL SECTION
Synthesis of 1,8-Diazido-3,6-dioxaoctane (5). 4-Tolue-
nesulfonyl chloride (3.3 g, 17.3 mmol, 2.6 equiv) was added to
a solution of anhydrous pyridine (1.3 g) and triethylene glycol
(1.0 g, 6.7 mmol) in anhydrous DCM (10 mL), and the
mixture was left to stir under N2 overnight at room
temperature. The solution was then concentrated in vacuo
and was subjected to standard work-up (EtOAc). The resultant
solid powder was then puriﬁed by recrystallization (DCM/
petroleum ether) to give the 3,6-dioxaoctane-1,8-ditosylate as a
white powder (2.8 g, 92%). NMR spectra were consistent with
those reported.21 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 8
Hz, 4H), 7.34−7.31 (m, 4H), 4.14−4.10 (m, 4H), 3.68−3.63
(m, 4H), 3.51 (s, 4H), 2.43 (s, 6H). 13C NMR (100 MHz,
CDCl3): δ 144.76, 132.97, 129.76, 127.87, 70.62, 69.12, 68.68,
21.54. HRMS (ESI): Expected for C20H26Na1O8S2 (M + Na
+)
= m/z 481.0967. Found: m/z 481.0983.
Sodium azide (1.14 g, 17.4 mmol, 4 equiv) was added to a
solution of 3,6-dioxaoctane-1,8-ditosylate (2.0 g, 4.3 mmol) in
acetone/water (3:1, 24 mL), and the mixture was allowed to
stir at 37 °C overnight. The mixture was then concentrated
under reduced pressure to remove the acetone, and the product
was extracted using ethyl acetate (3 × 20 mL). The organic
extract was then washed with saturated brine solution, dried
over MgSO4, concentrated, and then puriﬁed by silica gel
chromatography (10 → 60% EtOAc/petroleum ether) to give
the diazide (5) as a colorless oil (0.70 g, 80%). NMR spectra
were consistent with those reported.21 1H NMR (400 MHz,
CDCl3): δ 3.69−3.67 (m, 8H), 3.37 (t, J = 8 Hz, 4H). 13C
NMR (100 MHz, CDCl3): δ 70.68, 70.06, 50.64. HRMS (ESI):
Expected for C6H12N6NaO2 (M + Na
+) = m/z 223.0919.
Found: m/z 223.0925.
Synthesis of 1,11-Diazido-3,6,9-trioxaundecane (6). 4-
Toluenesulfonyl chloride (2.5 g, 13.4 mmol, 2.6 equiv) was
added to a solution of anhydrous pyridine (1 g) and
tetraethylene glycol (1.0 g, 5.2 mmol) in anhydrous DCM
(10 mL), and the mixture was left to stir under N2 overnight at
room temperature. The solution was then concentrated in
vacuo and was subjected to standard work-up (EtOAc). The
resultant residue was then puriﬁed by silica gel chromatography
(10 → 60% EtOAc/petroleum ether) to give 3,6,9-
trioxaundecane-1,11-ditosylate as a colorless oil (2.2 g, 85%).
NMR spectra were consistent with those reported.21 1H NMR
(400 MHz, CDCl3): δ 7.74−7.71 (m, 4H), 7.30−7.72 (m, 4H),
4.11−4.08 (m, 4H), 3.62−3.60 (m, 4H), 3.56−3.43 (m, 8H),
2.38 (s, 6H). 13C NMR (100 MHz, CDCl3): δ 144.77, 132.90,
129.77, 127.81, 70.50, 69.26, 68.54, 21.51. HRMS (ESI):
Expected for C22H30S2O9 (M + Na
+) = m/z 525.1229. Found:
m/z 525.1279.
Sodium azide (1.04 g, 16.0 mmol, 4 equiv) was added to a
solution of 3,6,9-trioxaundecane-1,11-ditosylate (2.0 g, 4.0
mmol) in acetone/water (3:1, 24 mL), and the mixture was
allowed to stir at 37 °C overnight. The mixture was then
concentrated under reduced pressure to remove the acetone,
and the product was extracted using ethyl acetate (3 × 20 mL).
The organic extract was then washed with saturated brine
solution, dried over MgSO4, concentrated, and then puriﬁed by
silica gel chromatography (10→ 60% EtOAc/petroleum ether)
to give the diazide (6) as a colorless oil (0.80 g, 82%). NMR
spectra were consistent with those reported.21 1H NMR (400
MHz, CDCl3): δ 3.67−3.62 (m, 12H), 3.35 (t, J = 8 Hz, 4H).
13C NMR (100 MHz, CDCl3): δ 70.63, 70.62, 69.94, 50.59.
HRMS (ESI): Expected for C8H16N6NaO3 (M + Na
+) = m/z
267.118159. Found: m/z 267.1228.
Synthesis of 1,14-Diazido-3,6,9,12-tetraoxatetrade-
cane (7). 4-Toluenesulfonyl chloride (2.07 g, 10.9 mmol, 2.6
equiv) was added to a solution of anhydrous pyridine (0.8 g)
and pentaethylene glycol (1.0 g, 4.2 mmol) in anhydrous DCM
(10 mL), and the mixture was left to stir under N2 overnight at
room temperature. The solution was then concentrated in
vacuo and was subjected to standard work-up (EtOAc). The
resultant residue was then puriﬁed by silica gel chromatography
(10 → 60% EtOAc/petroleum ether) to give 3,6,9,12-
tetraoxatetradecane-1,14-ditosylate as a colorless oil (2.0 g,
87%). NMR spectra were consistent with those reported.21 1H
NMR (400 MHz, CDCl3): δ 7.78 (d, 4H, J = 8 Hz), 7.33 (t,
4H, J = 8 Hz), 4.14 (t, 4H, J = 8 Hz), 3.68−3.65 (m, 4H), 3.60
(t, 12H, J = 8 Hz), 2.43 (s, 6H). 13C NMR (100 MHz, CDCl3):
δ 144.71, 133.00, 129.94, 127.83, 70.68, 70.49, 69.81, 68.61,
21.55. HRMS (ESI): Expected for C24H34Na1O10S2 (M + H
+)
= m/z 547.1672. Found: m/z 547.1666.
Sodium azide (0.95 g, 14.6 mmol, 4 equiv) was added to a
solution of 3,6,9,12-tetraoxatetradecane-1,14-ditosylate (2.0 g,
3.7 mmol) in acetone/water (3:1, 24 mL), and the mixture was
allowed to stir at 37 °C overnight. The mixture was then
concentrated under reduced pressure to remove the acetone,
and the product was extracted using ethyl acetate (3 × 20 mL).
The organic extract was then washed with saturated brine
solution, dried over MgSO4, concentrated, and then puriﬁed by
silica gel chromatography (10→ 60% EtOAc/petroleum ether)
to give the diazide (7) as a colorless oil (0.85 g, 81%). NMR
spectra were consistent with those reported.21 1H NMR (400
MHz, CDCl3): δ 3.68−3.65 (m, 16H), 3.37 (t, 4H, J = 4.0 Hz).
13C NMR (100 MHz, CDCl3): δ 70.65, 70.62, 70.57, 69.95,
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50.64. HRMS (ESI): Expected for C10H2N6NaO4 (M + Na
+) =
m/z 311.1443. Found: m/z 311.1434.
Synthesis of 1,17-Diazido-3,6,9,12,15-pentaoxahepta-
decane (8). 4-Toluenesulfonyl chloride (1.73 g, 9.1 mmol, 2.6
equiv) was added to a solution of anhydrous pyridine (0.76 g)
and hexaethylene glycol (1.0 g, 3.5 mmol) in anhydrous DCM
(10 mL), and the mixture was left to stir under N2 overnight at
room temperature. The solution was then concentrated in
vacuo and was subjected to standard work-up (EtOAc). The
resultant residue was then puriﬁed by silica gel chromatography
(10 → 60% EtOAc/petroleum ether) to give 3,6,9,12,15-
pentaoxaheptadecane-1,17-ditosylate as a colorless oil (1.70 g,
82%). NMR spectra were consistent with those reported.21 1H
NMR (400 MHz, CDCl3): δ 7.77 (d, 4H, J = 8 Hz), 7.32 (d,
4H, J = 8 Hz), 4.15−4.12 (m, 4H), 3.68−3.55 (m, 20H), 2.42
(s, 6H, Me). 13C NMR (100 MHz, CDCl3): δ 144.70, 133.00,
129.74, 127.89, 70.67, 70.54, 70.49, 70.44, 69.18, 68.60, 21.55.
HRMS (ESI): Expected for C26H39O11S2 (M + H
+) = m/z
591.1934. Found: m/z 591.1928.
Sodium azide (0.88 g, 13.6 mmol, 4 equiv) was added to a
solution of 3,6,9,12,15-pentaoxaheptadecane-1,17-ditosylate
(2.0 g, 3.39 mmol) in acetone/water (3:1, 24 mL), and the
mixture was allowed to stir at 37 °C overnight. The mixture was
then concentrated under reduced pressure to remove the
acetone, and the product was extracted using ethyl acetate (3 ×
20 mL). The organic extract was then washed with saturated
brine solution, dried over MgSO4, concentrated, and then
puriﬁed by silica gel chromatography (10 → 60% EtOAc/
petroleum ether) to give the diazide (8) as a colorless oil (0.89
g, 79%). NMR spectra were consistent with those reported.21
1H NMR (400 MHz, CDCl3): δ 3.67−3.64 (m, 20H), 3.36 (t, J
= 4 Hz, 4H). 13C NMR (100 MHz, CDCl3): δ 70.48, 70.44,
69.87, 50.54. HRMS (ESI): Expected for C12H24N6NaO5 (M +
Na+) = m/z 355.1706. Found: m/z 355.1728.
Synthesis of 1-(14-Azido-3,6,9,12-tetraoxatetradec-1-
yl)-5-ethyl-3a,6a-dihydropyrrolo[3,4-d][1,2,3]-triazole-
4,6(1H,5H)-dione (10) and 1,1′-(3,6,9,12-Tetraoxatetra-
decane-1,14-diyl)bis(5-ethyl-3a,6a-dihydropyrrolo[3,4-
d][1,2,3]triazole-4,6(1H,5H)-dione) (11). 1,14-Diazido-
3,6,9,12-tetraoxatetradecane 7 (50.0 mg, 0.173 mmol) and N-
ethylmaleimide 9 (32.6 mg, 0.260 mmol, 1.5 equiv) were stirred
in aqueous sodium phosphate (0.1 M, pH 7.0, 2 mL) at room
temperature for 2.5 days. The reaction was diluted with water
(20 mL) and extracted with ethyl acetate (2 × 50 mL). The
organic layer was dried over MgSO4, ﬁltered, and concentrated.
The crude material was puriﬁed by silica gel chromatography
(10→ 60% EtOAc/petroleum ether) to yield 10 (30 mg, 42%)
and 11 (23 mg, 25%) as transparent oils. Compound 10: 1H
NMR (400 MHz, CDCl3): δ 5.49 (d, J = 11.0 Hz, 1H,
NCOCHNCH2), 4.62 (d, J = 11.0 Hz, 1H, NCOCHN2), 4.15−
4.09 (dt, J = 4.5, 15.1 Hz, 1H, NCHHCH2O), 4.00−3.93 (ddd,
J = 3.9, 7.9, 14.8 Hz, 1H, NCHHCH2O), 3.86−3.81 (m, 1H,
NCH2CHHO), 3.78−3.72 (m, 1H, NCH2CHHO), 3.65−3.55
(m, 14H), 3.50 (q, J = 7.2 Hz, 2H, NCH2CH3), 3.36 (t, J = 5.2
Hz, 2H, CH2CH2N3), 1.11 (t, J = 7.2 Hz, 3H, CH2CH3).
13C
NMR (100 MHz, CDCl3): δ 172.2, 170.6, 81.2, 70.58, 70.54,
70.41, 70.38, 70.32, 70.12, 69.87, 69.1, 58.5, 50.5, 48.1, 34.1,
12.7. HRMS (ESI): Expected for C16H27N7NaO6 (M + Na
+) =
m/z 436.1915. Found: m/z 436.1946. IR (thin ﬁlm): 2107,
1714 cm−1. HPLC: 5 → 100% MeCN in H2O (0.5 mL/min)
over 20 min; retention time = 13.50 min, purity = 98.3%.
Detection at 254 nm. Compound 11: 1H NMR (400 MHz,
CDCl3): δ 5.55 (d, J = 11.0 Hz, 1H, COCHNCH2), 5.54 (d, J =
11.0 Hz, 1H, COCHNCH2), 4.67 (d, J = 11.0 Hz, 1H,
COCHN2), 4.66 (d, J = 11.0 Hz, 1H, COCHN2), 4.19−4.12
(m, 2H, NCHHCH2O), 4.02−3.94 (m, 2H, NCHHCH2O),
3.89−3.83 (m, 2H, NCH2CHHO), 3.80−3.74 (m, 2H,
NCH2CHHO), 3.68−3.56 (m, 12H), 3.53 (q, J = 7.2 Hz,
4H, NCH2CH3), 1.14 (t, J = 7.2 Hz, 6H, CH2CH3).
13C NMR
(100 MHz, CDCl3): δ 172.41, 172.39, 170.79, 170.73, 81.34,
81.33, 70.49, 70.36, 70.08, 69.21, 69.06, 58.62, 58.59, 48.14,
48.12, 34.24, 12.76. HRMS (ESI): Expected for C22H34N8NaO8
(M + Na+) = m/z 561.2392. Found: m/z 561.2365. IR (thin
ﬁlm): 1714 cm−1. HPLC: 5 → 100% MeCN in H2O (0.5 mL/
min) over 20 min; retention time = 13.53 min, purity = 99.4%.
Detection at 254 nm.
Rates of TCEP Oxidation by PEG-Azides (5−8). Control.
The rate of background (aerial) oxidation of TCEP was initially
evaluated. A solution of TCEP (100 mM) in Tris−HCl buﬀer
(0.1 M, pH 7) was held at 37 °C, and the mixture was analyzed
at 3 and 63 min using 31P NMR spectroscopy to quantify the
levels of phosphine oxide present. No oxidation of TCEP was
observed under these conditions (Figure S1).
PEG-Azide-Promoted Oxidation of TCEP. A solution of
TCEP−HCl (14 mg, 50 μmol) and PEG-azide (500 μmol, 10
equiv) in 0.1 M Tris−HCl buﬀer (2 mL, pH 7) was held at 37
°C, and the solution was analyzed by 31P NMR spectroscopy at
times 3, 13, 23, 33, 43, 53, and 63 min. The level of TCEP
oxidation was calculated by comparison of integrals corre-
sponding to the phosphine and phosphine oxide. It should be
noted that PEG-azide 5 was only partially soluble under these
conditions.
PEG-Azide-Promoted Oxidation of THPP. A solution of
THPP (10 mg, 48 μmol) and PEG-azide 8 (40 mg, 120 μmol,
2.5 equiv) in 0.1 M Tris−HCl buﬀer (2 mL, pH 7) was held at
37 °C, and the solution was analyzed by 31P NMR spectroscopy
at time 3 min. Complete conversion to the phosphine oxide
was observed at this time as no signal corresponding to the
remaining phosphine was present.
Fluorescent Labeling of Yeast Enolase in the
Absence/Presence of PEG-Azide (7). Denaturation of
Yeast Enolase Protein. A solution of yeast enolase (1 mg/mL)
in deoxygenated Tris−HCl buﬀer (0.5 M, pH 7.2, 5 mM
EDTA) containing 8 M urea was heated to 85 °C and held at
this temperature for 15 min. The solution was allowed to cool
to room temperature before use in subsequent experiments.
Labeling of Yeast Enolase with Maleimide Fluorescein
(11) Following Reduction with TCEP or THPP. Aliquots (100
μL) of denatured yeast enolase (1 mg/mL, 11 μM) were
treated with varying concentrations of TCEP or THPP (1−10
mM) and incubated for 45 min at 25 °C. Maleimide ﬂuorescein
11 (1 mM) was subsequently added to the enolase solutions at
each phosphine concentration and incubated at 37 °C for 18 h.
Samples (15 μL) were taken from each of the reactions and
added to the Laemmli sample buﬀer (15 μL) and heated (85
°C, 8 min). Aliquots (9 μL) of these solutions were then loaded
into a precast gradient gel (4−12% Bis-Tris, Invitrogen) along
with a protein ladder (EZ-Run, Fisher Scientiﬁc) and resolved
by SDS Page electrophoresis [MOPS running buﬀer (In-
vitrogen), 180 V, 60 min]. The precast gels were ﬁrst stained by
Coomassie solution and destained using a water/ethanol/acetic
acid (16:3:1) solution to conﬁrm equal protein loading.
Fluorescence was then visualized at 525 nm (Dark Reader).
Labeling of Yeast Enolase with Maleimide Fluorescein
(11) Following Quenching of TCEP or THPP with PEG-Azide
(7). Aliquots (100 μL) of denatured yeast enolase (1 mg/mL,
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11 μM) were treated with varying concentrations of TCEP or
THPP (1−10 mM) and incubated for 45 min at 25 °C.
Samples were then treated with PEG-azide 7 (100 mM) and
held for 1 hour at 37 °C. Maleimide-ﬂuorescein (1 mM) was
subsequently added to these solutions and incubated at 37 °C
for 18 h. Samples (15 μL) were taken from each of the
reactions and added to the Laemmli sample buﬀer (15 μL) and
heated (85 °C, 8 min). Aliquots (9 μL) of these solutions were
loaded into a precast gradient gel (4−12% Bis-Tris, Invitrogen)
along with a protein ladder (EZ-Run, Fisher Scientiﬁc) and
resolved by SDS Page electrophoresis [MOPS running buﬀer
(Invitrogen), 180 V, 60 min]. The precast gels were stained by
the Coomassie solution and destained using a water/ethanol/
acetic acid (16:3:1) solution to conﬁrm equal protein loading.
Fluorescence was then visualized at 525 nm (Dark Reader).
PEGylation of Yeast Enolase in the Absence/Presence
of Azide (7) Following Reduction by TCEP or THPP.
Labeling of Yeast Enolase with 2 kDa-PEG Maleimide
Following Reduction with TCEP or THPP. Aliquots (100 μL)
of denatured yeast enolase (1 mg/mL, 11 μM) were treated
with varying concentrations of TCEP or THPP (1−10 mM)
and incubated for 45 min at 25 °C. 2 kDa-PEG maleimide (1
mM) was subsequently added to the enolase solutions at each
phosphine concentration and incubated at 37 °C for 18 h.
Samples (15 μL) were taken from each of the reactions and
added to the Laemmli sample buﬀer (15 μL) and heated (85
°C, 8 min). Aliquots (9 μL) of these solutions were loaded into
a precast gradient gel (4−12% Bis-Tris, Invitrogen) along with
a protein ladder (EZ-Run, Fisher Scientiﬁc) and resolved by
SDS Page electrophoresis [MOPS running buﬀer (Invitrogen),
180 V, 60 min]. The precast gels were stained by the
Coomassie solution and destained using a water/ethanol/acetic
acid (16:3:1) solution. The gel was then scanned using a LI-
COR Odyssey CLx to quantify PEGylated enolase (Image
Studio Lite).
Labeling of Yeast Enolase with 2 kDa-PEG Maleimide
Following Quenching of TCEP or THPP with PEG-Azide (7).
Aliquots (100 μL) of denatured yeast enolase (1 mg/mL, 11
μM) were treated with varying concentrations of TCEP or
THPP (1−10 mM) and incubated for 45 min at 25 °C.
Samples were then treated with PEG-azide 7 (100 mM) and
held for 1 hour at 37 °C. 2 kDa-PEG maleimide (1 mM) was
subsequently added to these solutions and incubated at 37 °C
for 18 h. Samples (15 μL) were taken from each of the
reactions and added to the Laemmli sample buﬀer (15 μL) and
heated (85 °C, 8 min). Aliquots (9 μL) of these solutions were
loaded into a precast gradient gel (4−12% Bis-Tris, Invitrogen)
along with a protein ladder (EZ-Run, Fisher Scientiﬁc) and
resolved by SDS Page electrophoresis [MOPS running buﬀer
(Invitrogen), 180 V, 60 min]. The precast gels were stained by
the Coomassie solution and destained using a water/ethanol/
acetic acid (16:3:1) solution. The gel was then scanned using a
LI-COR Odyssey CLx to quantify PEGylated enolase (Image
Studio Lite).
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